HomeEDIT • NASDAQ
Editas Medicine Inc
add
$1.51
8.24%
After Hours:(0.026%)-0.00040
$1.51
Closed: May 16, 8:00:00 PM UTC-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 4.66M | 310.40% |
Operating expense | 39.06M | -40.11% |
Net income | -76.09M | -22.82% |
Net profit margin | -1.63K | 70.07% |
Earnings per share | -0.92 | -21.05% |
EBITDA | -33.39M | 49.08% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 220.96M | -25.39% |
Total assets | 263.65M | -40.13% |
Total liabilities | 201.23M | 37.88% |
Total equity | 62.42M | — |
Shares outstanding | 83.71M | — |
Price to book | 1.86 | — |
Return on assets | -29.17% | — |
Return on capital | -67.17% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -76.09M | -22.82% |
Cash from operations | -47.80M | 4.16% |
Cash from investing | 56.39M | 1,288.35% |
Cash from financing | -1.44M | -848.44% |
Net change in cash | 7.15M | 113.14% |
Free cash flow | -5.77M | 75.28% |
Previous close
$1.40
Day range
$1.35 - $1.51
Year range
$0.91 - $6.22
Market cap
125.95M USD
Avg Volume
2.04M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
Founded
Nov 2013
Website
Employees
246
